Anti-myopia effect of 0.01% atropine over placebo affected spherical equivalent (SE) but not axial length (AL) elongation in both ATOM2 study and LAMP study. It is possible that atropine might exert its effect through changes in corneal properties or lens power.
To evaluate changes of ocular biometrics in the 0.05%, 0.025%, and 0.01% atropine groups compared to placebo over one year based on the LAMP study.
Double-blinded, randomized, placebo-controlled trial.
383 children aged 4 to 12 years, who were randomly assigned to receive 0.05%, 0.025%, 0.01% atropine, or placebo once daily in both eyes and completed the first year of the LAMP study.
Cycloplegic SE, AL, corneal curvatures, and anterior chamber depth (ACD), were measured by IOL Master. Corneal astigmatism and lens power were calculated. The ocular biometric parameters changes were compared among various groups. Contributions to SE progression from ocular parameters were determined and compared among various groups.
Changes in ocular biometrics and their associations with the changes in SE.
Over one year, changes in AL were 0.20±0.25mm, 0.29±0.20mm, 0.36±0.29mm, and 0.41±0.22mm in 0.05%, 0.025%, 0.01% atropine and placebo, respectively (p0.05).
Low-concentrations of atropine 0.05%, 0.025%, and 0.01% have no clinical effect on corneal power and lens power. The anti-myopic effects of low-concentration atropine act mainly on reducing AL elongation, and therefore could reduce risk of subsequent myopia complications.
Copyright © 2020. Published by Elsevier Inc.